nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—PDGFRA—brain cancer	0.336	0.663	CbGaD
Imatinib—CYP2C9—brain cancer	0.171	0.336	CbGaD
Imatinib—CYP2D6—Lomustine—brain cancer	0.0262	0.134	CbGbCtD
Imatinib—CYP1A2—Carmustine—brain cancer	0.026	0.133	CbGbCtD
Imatinib—ABCG2—Carboplatin—brain cancer	0.0222	0.114	CbGbCtD
Imatinib—CYP2D6—Hydroxyurea—brain cancer	0.0199	0.102	CbGbCtD
Imatinib—CYP3A4—Temozolomide—brain cancer	0.0196	0.1	CbGbCtD
Imatinib—ABCG2—Etoposide—brain cancer	0.0187	0.0956	CbGbCtD
Imatinib—PTGS1—Etoposide—brain cancer	0.0172	0.0882	CbGbCtD
Imatinib—CYP3A4—Lomustine—brain cancer	0.0167	0.0854	CbGbCtD
Imatinib—CYP3A5—Etoposide—brain cancer	0.0103	0.0529	CbGbCtD
Imatinib—CYP1A2—Etoposide—brain cancer	0.00769	0.0394	CbGbCtD
Imatinib—ABCB1—Etoposide—brain cancer	0.00673	0.0345	CbGbCtD
Imatinib—CYP3A4—Etoposide—brain cancer	0.00403	0.0206	CbGbCtD
Imatinib—Ponatinib—PDGFRA—brain cancer	0.00188	0.473	CrCbGaD
Imatinib—Nilotinib—PDGFRA—brain cancer	0.00138	0.349	CrCbGaD
Imatinib—ABCA3—telencephalon—brain cancer	0.00112	0.0163	CbGeAlD
Imatinib—DDR1—telencephalon—brain cancer	0.00103	0.0151	CbGeAlD
Imatinib—NTRK1—midbrain—brain cancer	0.00101	0.0148	CbGeAlD
Imatinib—HIPK4—gonad—brain cancer	0.000941	0.0138	CbGeAlD
Imatinib—NQO2—hindbrain—brain cancer	0.000917	0.0134	CbGeAlD
Imatinib—ABCA3—pituitary gland—brain cancer	0.000908	0.0133	CbGeAlD
Imatinib—ABCA3—medulla oblongata—brain cancer	0.000876	0.0128	CbGeAlD
Imatinib—DDR1—pituitary gland—brain cancer	0.000838	0.0123	CbGeAlD
Imatinib—KIT—endothelium—brain cancer	0.000832	0.0122	CbGeAlD
Imatinib—SLC22A1—ganglion—brain cancer	0.000809	0.0119	CbGeAlD
Imatinib—DDR1—medulla oblongata—brain cancer	0.000809	0.0118	CbGeAlD
Imatinib—ABCA3—midbrain—brain cancer	0.000801	0.0117	CbGeAlD
Imatinib—ABCA3—spinal cord—brain cancer	0.000781	0.0114	CbGeAlD
Imatinib—KIT—blood vessel—brain cancer	0.000767	0.0112	CbGeAlD
Imatinib—PDGFRB—blood vessel—brain cancer	0.000749	0.011	CbGeAlD
Imatinib—DDR1—midbrain—brain cancer	0.000739	0.0108	CbGeAlD
Imatinib—SLC47A1—hindbrain—brain cancer	0.000736	0.0108	CbGeAlD
Imatinib—KIT—hindbrain—brain cancer	0.000731	0.0107	CbGeAlD
Imatinib—DDR1—spinal cord—brain cancer	0.000721	0.0106	CbGeAlD
Imatinib—HIPK4—endocrine gland—brain cancer	0.000711	0.0104	CbGeAlD
Imatinib—Nilotinib—CYP2C9—brain cancer	0.000702	0.177	CrCbGaD
Imatinib—ABCA3—head—brain cancer	0.000694	0.0102	CbGeAlD
Imatinib—ABL1—hindbrain—brain cancer	0.000637	0.00933	CbGeAlD
Imatinib—PIP4K2C—telencephalon—brain cancer	0.000635	0.00931	CbGeAlD
Imatinib—ABCA3—central nervous system—brain cancer	0.000634	0.00929	CbGeAlD
Imatinib—ABCA3—cerebellum—brain cancer	0.00062	0.00908	CbGeAlD
Imatinib—CA3—telencephalon—brain cancer	0.000607	0.00889	CbGeAlD
Imatinib—DDR1—cerebellum—brain cancer	0.000572	0.00838	CbGeAlD
Imatinib—CA14—telencephalon—brain cancer	0.000551	0.00807	CbGeAlD
Imatinib—ABL2—pituitary gland—brain cancer	0.000547	0.00801	CbGeAlD
Imatinib—PIP4K2C—gonad—brain cancer	0.00053	0.00777	CbGeAlD
Imatinib—NQO2—brainstem—brain cancer	0.000526	0.0077	CbGeAlD
Imatinib—PIP4K2C—pituitary gland—brain cancer	0.000517	0.00758	CbGeAlD
Imatinib—HIPK4—brain—brain cancer	0.000509	0.00746	CbGeAlD
Imatinib—ABCA3—brain—brain cancer	0.000503	0.00737	CbGeAlD
Imatinib—PIP4K2C—medulla oblongata—brain cancer	0.000499	0.00731	CbGeAlD
Imatinib—CA3—pituitary gland—brain cancer	0.000494	0.00723	CbGeAlD
Imatinib—CA7—midbrain—brain cancer	0.000475	0.00696	CbGeAlD
Imatinib—NQO2—telencephalon—brain cancer	0.000467	0.00683	CbGeAlD
Imatinib—PDGFRA—telencephalon—brain cancer	0.000465	0.00682	CbGeAlD
Imatinib—DDR1—brain—brain cancer	0.000464	0.0068	CbGeAlD
Imatinib—PIP4K2C—midbrain—brain cancer	0.000456	0.00668	CbGeAlD
Imatinib—PIP4K2C—spinal cord—brain cancer	0.000445	0.00652	CbGeAlD
Imatinib—PTGS1—ganglion—brain cancer	0.000442	0.00647	CbGeAlD
Imatinib—CA2—hindbrain—brain cancer	0.000434	0.00635	CbGeAlD
Imatinib—CA14—medulla oblongata—brain cancer	0.000433	0.00634	CbGeAlD
Imatinib—CA12—telencephalon—brain cancer	0.00043	0.00629	CbGeAlD
Imatinib—SLC47A1—brainstem—brain cancer	0.000422	0.00618	CbGeAlD
Imatinib—KIT—brainstem—brain cancer	0.000419	0.00614	CbGeAlD
Imatinib—CSF1R—telencephalon—brain cancer	0.00041	0.006	CbGeAlD
Imatinib—PIP4K2C—endocrine gland—brain cancer	0.000401	0.00587	CbGeAlD
Imatinib—CA6—head—brain cancer	0.000399	0.00584	CbGeAlD
Imatinib—PIP4K2C—head—brain cancer	0.000396	0.00579	CbGeAlD
Imatinib—CA14—midbrain—brain cancer	0.000396	0.00579	CbGeAlD
Imatinib—PDGFRA—gonad—brain cancer	0.000388	0.00569	CbGeAlD
Imatinib—CA14—spinal cord—brain cancer	0.000386	0.00565	CbGeAlD
Imatinib—CA3—endocrine gland—brain cancer	0.000383	0.0056	CbGeAlD
Imatinib—PTGS1—endothelium—brain cancer	0.000381	0.00558	CbGeAlD
Imatinib—NQO2—pituitary gland—brain cancer	0.00038	0.00556	CbGeAlD
Imatinib—CA3—head—brain cancer	0.000378	0.00553	CbGeAlD
Imatinib—ABL2—cerebellum—brain cancer	0.000373	0.00546	CbGeAlD
Imatinib—KIT—telencephalon—brain cancer	0.000372	0.00545	CbGeAlD
Imatinib—CA7—cerebellum—brain cancer	0.000367	0.00538	CbGeAlD
Imatinib—NQO2—medulla oblongata—brain cancer	0.000367	0.00537	CbGeAlD
Imatinib—CA9—endocrine gland—brain cancer	0.000366	0.00537	CbGeAlD
Imatinib—ABL1—brainstem—brain cancer	0.000365	0.00535	CbGeAlD
Imatinib—PDGFRB—telencephalon—brain cancer	0.000363	0.00532	CbGeAlD
Imatinib—PIP4K2C—central nervous system—brain cancer	0.000361	0.00529	CbGeAlD
Imatinib—PIP4K2C—cerebellum—brain cancer	0.000353	0.00517	CbGeAlD
Imatinib—PTGS1—blood vessel—brain cancer	0.000351	0.00514	CbGeAlD
Imatinib—CA3—central nervous system—brain cancer	0.000345	0.00505	CbGeAlD
Imatinib—CSF1R—gonad—brain cancer	0.000342	0.00501	CbGeAlD
Imatinib—CA1—telencephalon—brain cancer	0.00034	0.00498	CbGeAlD
Imatinib—CYP3A7—endocrine gland—brain cancer	0.00034	0.00498	CbGeAlD
Imatinib—NQO2—midbrain—brain cancer	0.000335	0.00491	CbGeAlD
Imatinib—CSF1R—pituitary gland—brain cancer	0.000334	0.00489	CbGeAlD
Imatinib—NQO2—spinal cord—brain cancer	0.000327	0.00479	CbGeAlD
Imatinib—PDGFRA—spinal cord—brain cancer	0.000326	0.00478	CbGeAlD
Imatinib—ABL1—telencephalon—brain cancer	0.000324	0.00474	CbGeAlD
Imatinib—CA9—cerebellum—brain cancer	0.000323	0.00473	CbGeAlD
Imatinib—CSF1R—medulla oblongata—brain cancer	0.000322	0.00472	CbGeAlD
Imatinib—SLC47A1—gonad—brain cancer	0.000312	0.00457	CbGeAlD
Imatinib—SLC22A1—telencephalon—brain cancer	0.000312	0.00457	CbGeAlD
Imatinib—KIT—gonad—brain cancer	0.000311	0.00455	CbGeAlD
Imatinib—CA14—cerebellum—brain cancer	0.000306	0.00448	CbGeAlD
Imatinib—SLC47A1—pituitary gland—brain cancer	0.000305	0.00446	CbGeAlD
Imatinib—PDGFRB—gonad—brain cancer	0.000303	0.00444	CbGeAlD
Imatinib—ABL2—brain—brain cancer	0.000303	0.00444	CbGeAlD
Imatinib—KIT—pituitary gland—brain cancer	0.000303	0.00444	CbGeAlD
Imatinib—CA7—brain—brain cancer	0.000298	0.00437	CbGeAlD
Imatinib—PDGFRB—pituitary gland—brain cancer	0.000296	0.00433	CbGeAlD
Imatinib—NQO2—endocrine gland—brain cancer	0.000294	0.00431	CbGeAlD
Imatinib—CSF1R—midbrain—brain cancer	0.000294	0.00431	CbGeAlD
Imatinib—SLC47A1—medulla oblongata—brain cancer	0.000294	0.00431	CbGeAlD
Imatinib—PDGFRA—endocrine gland—brain cancer	0.000294	0.0043	CbGeAlD
Imatinib—KIT—medulla oblongata—brain cancer	0.000292	0.00428	CbGeAlD
Imatinib—NQO2—head—brain cancer	0.000291	0.00426	CbGeAlD
Imatinib—PDGFRA—head—brain cancer	0.00029	0.00425	CbGeAlD
Imatinib—CSF1R—spinal cord—brain cancer	0.000287	0.00421	CbGeAlD
Imatinib—PIP4K2C—brain—brain cancer	0.000287	0.0042	CbGeAlD
Imatinib—PDGFRB—medulla oblongata—brain cancer	0.000286	0.00418	CbGeAlD
Imatinib—CYP2D6—hindbrain—brain cancer	0.000275	0.00403	CbGeAlD
Imatinib—CA3—brain—brain cancer	0.000274	0.00401	CbGeAlD
Imatinib—CA12—endocrine gland—brain cancer	0.000271	0.00397	CbGeAlD
Imatinib—ABL1—gonad—brain cancer	0.00027	0.00396	CbGeAlD
Imatinib—CA12—head—brain cancer	0.000267	0.00392	CbGeAlD
Imatinib—KIT—midbrain—brain cancer	0.000267	0.00391	CbGeAlD
Imatinib—NQO2—central nervous system—brain cancer	0.000265	0.00388	CbGeAlD
Imatinib—PDGFRA—central nervous system—brain cancer	0.000265	0.00387	CbGeAlD
Imatinib—ABL1—pituitary gland—brain cancer	0.000264	0.00386	CbGeAlD
Imatinib—SLC47A1—spinal cord—brain cancer	0.000262	0.00384	CbGeAlD
Imatinib—PDGFRB—midbrain—brain cancer	0.000261	0.00382	CbGeAlD
Imatinib—KIT—spinal cord—brain cancer	0.000261	0.00382	CbGeAlD
Imatinib—NQO2—cerebellum—brain cancer	0.000259	0.0038	CbGeAlD
Imatinib—PDGFRA—cerebellum—brain cancer	0.000259	0.00379	CbGeAlD
Imatinib—CSF1R—endocrine gland—brain cancer	0.000258	0.00379	CbGeAlD
Imatinib—CSF1R—head—brain cancer	0.000255	0.00374	CbGeAlD
Imatinib—PDGFRB—spinal cord—brain cancer	0.000255	0.00373	CbGeAlD
Imatinib—ABL1—medulla oblongata—brain cancer	0.000254	0.00373	CbGeAlD
Imatinib—CA14—brain—brain cancer	0.000249	0.00364	CbGeAlD
Imatinib—CA2—brainstem—brain cancer	0.000249	0.00364	CbGeAlD
Imatinib—CA12—central nervous system—brain cancer	0.000244	0.00358	CbGeAlD
Imatinib—ORM1—spinal cord—brain cancer	0.000239	0.0035	CbGeAlD
Imatinib—CA1—spinal cord—brain cancer	0.000238	0.00349	CbGeAlD
Imatinib—SLC47A1—endocrine gland—brain cancer	0.000236	0.00346	CbGeAlD
Imatinib—KIT—endocrine gland—brain cancer	0.000235	0.00344	CbGeAlD
Imatinib—SLC47A1—head—brain cancer	0.000233	0.00341	CbGeAlD
Imatinib—CSF1R—central nervous system—brain cancer	0.000233	0.00341	CbGeAlD
Imatinib—ABL1—midbrain—brain cancer	0.000233	0.00341	CbGeAlD
Imatinib—KIT—head—brain cancer	0.000232	0.00339	CbGeAlD
Imatinib—PDGFRB—endocrine gland—brain cancer	0.000229	0.00336	CbGeAlD
Imatinib—CSF1R—cerebellum—brain cancer	0.000228	0.00333	CbGeAlD
Imatinib—ABL1—spinal cord—brain cancer	0.000227	0.00332	CbGeAlD
Imatinib—PDGFRB—head—brain cancer	0.000226	0.00331	CbGeAlD
Imatinib—CA2—telencephalon—brain cancer	0.000221	0.00323	CbGeAlD
Imatinib—ORM1—endocrine gland—brain cancer	0.000215	0.00315	CbGeAlD
Imatinib—CA1—endocrine gland—brain cancer	0.000215	0.00314	CbGeAlD
Imatinib—SLC47A1—central nervous system—brain cancer	0.000213	0.00312	CbGeAlD
Imatinib—CA1—head—brain cancer	0.000212	0.0031	CbGeAlD
Imatinib—KIT—central nervous system—brain cancer	0.000211	0.0031	CbGeAlD
Imatinib—NQO2—brain—brain cancer	0.000211	0.00308	CbGeAlD
Imatinib—PDGFRA—brain—brain cancer	0.00021	0.00308	CbGeAlD
Imatinib—SLC47A1—cerebellum—brain cancer	0.000208	0.00305	CbGeAlD
Imatinib—ABCB1—blood vessel—brain cancer	0.000208	0.00304	CbGeAlD
Imatinib—KIT—cerebellum—brain cancer	0.000207	0.00303	CbGeAlD
Imatinib—PDGFRB—central nervous system—brain cancer	0.000207	0.00303	CbGeAlD
Imatinib—ABL1—endocrine gland—brain cancer	0.000204	0.00299	CbGeAlD
Imatinib—ABCG2—telencephalon—brain cancer	0.000204	0.00299	CbGeAlD
Imatinib—PDGFRB—cerebellum—brain cancer	0.000202	0.00296	CbGeAlD
Imatinib—ABL1—head—brain cancer	0.000202	0.00295	CbGeAlD
Imatinib—SLC22A1—endocrine gland—brain cancer	0.000197	0.00288	CbGeAlD
Imatinib—SLC22A1—head—brain cancer	0.000194	0.00285	CbGeAlD
Imatinib—CA12—brain—brain cancer	0.000194	0.00284	CbGeAlD
Imatinib—ORM1—central nervous system—brain cancer	0.000194	0.00284	CbGeAlD
Imatinib—CA1—central nervous system—brain cancer	0.000193	0.00283	CbGeAlD
Imatinib—CSF1R—brain—brain cancer	0.000185	0.00271	CbGeAlD
Imatinib—ABL1—central nervous system—brain cancer	0.000184	0.0027	CbGeAlD
Imatinib—ABL1—cerebellum—brain cancer	0.00018	0.00264	CbGeAlD
Imatinib—CA2—pituitary gland—brain cancer	0.00018	0.00263	CbGeAlD
Imatinib—SLC22A1—central nervous system—brain cancer	0.000177	0.0026	CbGeAlD
Imatinib—CA2—medulla oblongata—brain cancer	0.000173	0.00254	CbGeAlD
Imatinib—PTGS1—telencephalon—brain cancer	0.00017	0.0025	CbGeAlD
Imatinib—SLC47A1—brain—brain cancer	0.000169	0.00247	CbGeAlD
Imatinib—KIT—brain—brain cancer	0.000168	0.00246	CbGeAlD
Imatinib—ABCG2—pituitary gland—brain cancer	0.000166	0.00244	CbGeAlD
Imatinib—PDGFRB—brain—brain cancer	0.000164	0.0024	CbGeAlD
Imatinib—ABCG2—medulla oblongata—brain cancer	0.00016	0.00235	CbGeAlD
Imatinib—CA2—midbrain—brain cancer	0.000158	0.00232	CbGeAlD
Imatinib—CYP2D6—brainstem—brain cancer	0.000158	0.00231	CbGeAlD
Imatinib—Decreased appetite—Procarbazine—brain cancer	0.000156	0.00114	CcSEcCtD
Imatinib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000156	0.00114	CcSEcCtD
Imatinib—Oedema peripheral—Carmustine—brain cancer	0.000156	0.00114	CcSEcCtD
Imatinib—Connective tissue disorder—Carmustine—brain cancer	0.000155	0.00114	CcSEcCtD
Imatinib—Fatigue—Procarbazine—brain cancer	0.000155	0.00113	CcSEcCtD
Imatinib—CA2—spinal cord—brain cancer	0.000155	0.00226	CbGeAlD
Imatinib—CA1—brain—brain cancer	0.000154	0.00225	CbGeAlD
Imatinib—Haemoglobin—Temozolomide—brain cancer	0.000153	0.00113	CcSEcCtD
Imatinib—Malaise—Hydroxyurea—brain cancer	0.000153	0.00113	CcSEcCtD
Imatinib—Pain—Procarbazine—brain cancer	0.000153	0.00113	CcSEcCtD
Imatinib—Constipation—Procarbazine—brain cancer	0.000153	0.00113	CcSEcCtD
Imatinib—Hepatitis—Temozolomide—brain cancer	0.000153	0.00112	CcSEcCtD
Imatinib—Haemorrhage—Temozolomide—brain cancer	0.000153	0.00112	CcSEcCtD
Imatinib—Dysphagia—Etoposide—brain cancer	0.000153	0.00112	CcSEcCtD
Imatinib—Leukopenia—Hydroxyurea—brain cancer	0.000152	0.00112	CcSEcCtD
Imatinib—CYP2C19—endocrine gland—brain cancer	0.000152	0.00222	CbGeAlD
Imatinib—Hypoaesthesia—Temozolomide—brain cancer	0.000152	0.00111	CcSEcCtD
Imatinib—Pharyngitis—Temozolomide—brain cancer	0.000151	0.00111	CcSEcCtD
Imatinib—Urinary tract disorder—Temozolomide—brain cancer	0.000151	0.00111	CcSEcCtD
Imatinib—Oedema peripheral—Temozolomide—brain cancer	0.00015	0.0011	CcSEcCtD
Imatinib—Connective tissue disorder—Temozolomide—brain cancer	0.00015	0.0011	CcSEcCtD
Imatinib—Urethral disorder—Temozolomide—brain cancer	0.00015	0.0011	CcSEcCtD
Imatinib—Sweating increased—Etoposide—brain cancer	0.000149	0.00109	CcSEcCtD
Imatinib—Feeling abnormal—Procarbazine—brain cancer	0.000148	0.00108	CcSEcCtD
Imatinib—Eye disorder—Carmustine—brain cancer	0.000148	0.00108	CcSEcCtD
Imatinib—Convulsion—Hydroxyurea—brain cancer	0.000147	0.00108	CcSEcCtD
Imatinib—ABCG2—midbrain—brain cancer	0.000147	0.00215	CbGeAlD
Imatinib—Gastrointestinal pain—Procarbazine—brain cancer	0.000147	0.00108	CcSEcCtD
Imatinib—Flushing—Carmustine—brain cancer	0.000147	0.00108	CcSEcCtD
Imatinib—ABL1—brain—brain cancer	0.000146	0.00214	CbGeAlD
Imatinib—Pancytopenia—Etoposide—brain cancer	0.000145	0.00106	CcSEcCtD
Imatinib—Erythema multiforme—Temozolomide—brain cancer	0.000144	0.00106	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000144	0.00105	CcSEcCtD
Imatinib—ABCG2—spinal cord—brain cancer	0.000143	0.0021	CbGeAlD
Imatinib—Discomfort—Hydroxyurea—brain cancer	0.000143	0.00105	CcSEcCtD
Imatinib—Neutropenia—Etoposide—brain cancer	0.000143	0.00105	CcSEcCtD
Imatinib—Eye disorder—Temozolomide—brain cancer	0.000143	0.00105	CcSEcCtD
Imatinib—Urticaria—Procarbazine—brain cancer	0.000142	0.00105	CcSEcCtD
Imatinib—Tinnitus—Temozolomide—brain cancer	0.000142	0.00104	CcSEcCtD
Imatinib—Abdominal pain—Procarbazine—brain cancer	0.000142	0.00104	CcSEcCtD
Imatinib—Body temperature increased—Procarbazine—brain cancer	0.000142	0.00104	CcSEcCtD
Imatinib—Cardiac disorder—Temozolomide—brain cancer	0.000142	0.00104	CcSEcCtD
Imatinib—Flushing—Temozolomide—brain cancer	0.000142	0.00104	CcSEcCtD
Imatinib—Arrhythmia—Carmustine—brain cancer	0.000141	0.00104	CcSEcCtD
Imatinib—SLC22A1—brain—brain cancer	0.000141	0.00206	CbGeAlD
Imatinib—CYP2D6—telencephalon—brain cancer	0.00014	0.00205	CbGeAlD
Imatinib—Alopecia—Carmustine—brain cancer	0.00014	0.00102	CcSEcCtD
Imatinib—CA2—endocrine gland—brain cancer	0.000139	0.00204	CbGeAlD
Imatinib—Oedema—Hydroxyurea—brain cancer	0.000139	0.00102	CcSEcCtD
Imatinib—PTGS1—pituitary gland—brain cancer	0.000139	0.00203	CbGeAlD
Imatinib—Angiopathy—Temozolomide—brain cancer	0.000138	0.00102	CcSEcCtD
Imatinib—Mental disorder—Carmustine—brain cancer	0.000138	0.00102	CcSEcCtD
Imatinib—Infection—Hydroxyurea—brain cancer	0.000138	0.00101	CcSEcCtD
Imatinib—Immune system disorder—Temozolomide—brain cancer	0.000138	0.00101	CcSEcCtD
Imatinib—Mediastinal disorder—Temozolomide—brain cancer	0.000138	0.00101	CcSEcCtD
Imatinib—Erythema—Carmustine—brain cancer	0.000137	0.00101	CcSEcCtD
Imatinib—Malnutrition—Carmustine—brain cancer	0.000137	0.00101	CcSEcCtD
Imatinib—CA2—head—brain cancer	0.000137	0.00201	CbGeAlD
Imatinib—Chills—Temozolomide—brain cancer	0.000137	0.001	CcSEcCtD
Imatinib—Pneumonia—Etoposide—brain cancer	0.000137	0.001	CcSEcCtD
Imatinib—Nervous system disorder—Hydroxyurea—brain cancer	0.000136	0.000999	CcSEcCtD
Imatinib—Infestation—Etoposide—brain cancer	0.000136	0.000998	CcSEcCtD
Imatinib—Infestation NOS—Etoposide—brain cancer	0.000136	0.000998	CcSEcCtD
Imatinib—Thrombocytopenia—Hydroxyurea—brain cancer	0.000136	0.000997	CcSEcCtD
Imatinib—ALB—brain—brain cancer	0.000135	0.00198	CbGeAlD
Imatinib—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000135	0.00099	CcSEcCtD
Imatinib—Alopecia—Temozolomide—brain cancer	0.000135	0.00099	CcSEcCtD
Imatinib—Skin disorder—Hydroxyurea—brain cancer	0.000135	0.000989	CcSEcCtD
Imatinib—Acute coronary syndrome—Etoposide—brain cancer	0.000134	0.000984	CcSEcCtD
Imatinib—Renal failure—Etoposide—brain cancer	0.000134	0.000981	CcSEcCtD
Imatinib—Mental disorder—Temozolomide—brain cancer	0.000134	0.000981	CcSEcCtD
Imatinib—Myocardial infarction—Etoposide—brain cancer	0.000133	0.000978	CcSEcCtD
Imatinib—Neuropathy peripheral—Etoposide—brain cancer	0.000133	0.000978	CcSEcCtD
Imatinib—Back pain—Carmustine—brain cancer	0.000133	0.000976	CcSEcCtD
Imatinib—Malnutrition—Temozolomide—brain cancer	0.000133	0.000975	CcSEcCtD
Imatinib—Erythema—Temozolomide—brain cancer	0.000133	0.000975	CcSEcCtD
Imatinib—Stomatitis—Etoposide—brain cancer	0.000133	0.000973	CcSEcCtD
Imatinib—Jaundice—Etoposide—brain cancer	0.000133	0.000973	CcSEcCtD
Imatinib—Anorexia—Hydroxyurea—brain cancer	0.000132	0.000971	CcSEcCtD
Imatinib—Hypersensitivity—Procarbazine—brain cancer	0.000132	0.000969	CcSEcCtD
Imatinib—Dysgeusia—Temozolomide—brain cancer	0.00013	0.000955	CcSEcCtD
Imatinib—Vision blurred—Carmustine—brain cancer	0.00013	0.000951	CcSEcCtD
Imatinib—Tremor—Carmustine—brain cancer	0.000129	0.000945	CcSEcCtD
Imatinib—Asthenia—Procarbazine—brain cancer	0.000129	0.000944	CcSEcCtD
Imatinib—Hepatobiliary disease—Etoposide—brain cancer	0.000129	0.000944	CcSEcCtD
Imatinib—Back pain—Temozolomide—brain cancer	0.000128	0.000943	CcSEcCtD
Imatinib—Anaemia—Carmustine—brain cancer	0.000127	0.000932	CcSEcCtD
Imatinib—Agranulocytosis—Etoposide—brain cancer	0.000127	0.000931	CcSEcCtD
Imatinib—Pruritus—Procarbazine—brain cancer	0.000127	0.000931	CcSEcCtD
Imatinib—CA2—central nervous system—brain cancer	0.000125	0.00184	CbGeAlD
Imatinib—Vision blurred—Temozolomide—brain cancer	0.000125	0.000919	CcSEcCtD
Imatinib—Tremor—Temozolomide—brain cancer	0.000124	0.000913	CcSEcCtD
Imatinib—CYP1A2—endocrine gland—brain cancer	0.000124	0.00182	CbGeAlD
Imatinib—Dyspnoea—Hydroxyurea—brain cancer	0.000124	0.000908	CcSEcCtD
Imatinib—Somnolence—Hydroxyurea—brain cancer	0.000123	0.000905	CcSEcCtD
Imatinib—Ill-defined disorder—Temozolomide—brain cancer	0.000123	0.000904	CcSEcCtD
Imatinib—Leukopenia—Carmustine—brain cancer	0.000123	0.000903	CcSEcCtD
Imatinib—Anaemia—Temozolomide—brain cancer	0.000123	0.000901	CcSEcCtD
Imatinib—Diarrhoea—Procarbazine—brain cancer	0.000123	0.0009	CcSEcCtD
Imatinib—CA2—cerebellum—brain cancer	0.000123	0.00179	CbGeAlD
Imatinib—Dyspepsia—Hydroxyurea—brain cancer	0.000122	0.000896	CcSEcCtD
Imatinib—Hypoaesthesia—Etoposide—brain cancer	0.000121	0.000892	CcSEcCtD
Imatinib—Angioedema—Temozolomide—brain cancer	0.000121	0.000891	CcSEcCtD
Imatinib—Decreased appetite—Hydroxyurea—brain cancer	0.000121	0.000885	CcSEcCtD
Imatinib—Urinary tract disorder—Etoposide—brain cancer	0.000121	0.000885	CcSEcCtD
Imatinib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00012	0.000879	CcSEcCtD
Imatinib—Malaise—Temozolomide—brain cancer	0.00012	0.000879	CcSEcCtD
Imatinib—Urethral disorder—Etoposide—brain cancer	0.00012	0.000878	CcSEcCtD
Imatinib—Fatigue—Hydroxyurea—brain cancer	0.00012	0.000878	CcSEcCtD
Imatinib—CYP3A5—endocrine gland—brain cancer	0.00012	0.00175	CbGeAlD
Imatinib—PTGS1—spinal cord—brain cancer	0.000119	0.00175	CbGeAlD
Imatinib—Vertigo—Temozolomide—brain cancer	0.000119	0.000876	CcSEcCtD
Imatinib—Convulsion—Carmustine—brain cancer	0.000119	0.000874	CcSEcCtD
Imatinib—Leukopenia—Temozolomide—brain cancer	0.000119	0.000873	CcSEcCtD
Imatinib—Hypertension—Carmustine—brain cancer	0.000119	0.000871	CcSEcCtD
Imatinib—Constipation—Hydroxyurea—brain cancer	0.000119	0.000871	CcSEcCtD
Imatinib—Pain—Hydroxyurea—brain cancer	0.000119	0.000871	CcSEcCtD
Imatinib—Dizziness—Procarbazine—brain cancer	0.000119	0.00087	CcSEcCtD
Imatinib—CYP2C9—endocrine gland—brain cancer	0.000118	0.00172	CbGeAlD
Imatinib—Palpitations—Temozolomide—brain cancer	0.000117	0.000861	CcSEcCtD
Imatinib—Chest pain—Carmustine—brain cancer	0.000117	0.000859	CcSEcCtD
Imatinib—Myalgia—Carmustine—brain cancer	0.000117	0.000859	CcSEcCtD
Imatinib—Anxiety—Carmustine—brain cancer	0.000117	0.000856	CcSEcCtD
Imatinib—Cough—Temozolomide—brain cancer	0.000116	0.000851	CcSEcCtD
Imatinib—Erythema multiforme—Etoposide—brain cancer	0.000115	0.000847	CcSEcCtD
Imatinib—Convulsion—Temozolomide—brain cancer	0.000115	0.000845	CcSEcCtD
Imatinib—Hypertension—Temozolomide—brain cancer	0.000115	0.000842	CcSEcCtD
Imatinib—Feeling abnormal—Hydroxyurea—brain cancer	0.000114	0.000839	CcSEcCtD
Imatinib—Eye disorder—Etoposide—brain cancer	0.000114	0.000837	CcSEcCtD
Imatinib—Vomiting—Procarbazine—brain cancer	0.000114	0.000837	CcSEcCtD
Imatinib—ABCG2—cerebellum—brain cancer	0.000113	0.00166	CbGeAlD
Imatinib—Cardiac disorder—Etoposide—brain cancer	0.000113	0.000832	CcSEcCtD
Imatinib—Flushing—Etoposide—brain cancer	0.000113	0.000832	CcSEcCtD
Imatinib—Confusional state—Carmustine—brain cancer	0.000113	0.00083	CcSEcCtD
Imatinib—Myalgia—Temozolomide—brain cancer	0.000113	0.00083	CcSEcCtD
Imatinib—Arthralgia—Temozolomide—brain cancer	0.000113	0.00083	CcSEcCtD
Imatinib—Rash—Procarbazine—brain cancer	0.000113	0.00083	CcSEcCtD
Imatinib—Dermatitis—Procarbazine—brain cancer	0.000113	0.000829	CcSEcCtD
Imatinib—Anxiety—Temozolomide—brain cancer	0.000113	0.000827	CcSEcCtD
Imatinib—Headache—Procarbazine—brain cancer	0.000112	0.000824	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000112	0.000824	CcSEcCtD
Imatinib—Oedema—Carmustine—brain cancer	0.000112	0.000823	CcSEcCtD
Imatinib—Discomfort—Temozolomide—brain cancer	0.000112	0.00082	CcSEcCtD
Imatinib—Infection—Carmustine—brain cancer	0.000111	0.000818	CcSEcCtD
Imatinib—Angiopathy—Etoposide—brain cancer	0.000111	0.000813	CcSEcCtD
Imatinib—Dry mouth—Temozolomide—brain cancer	0.000111	0.000812	CcSEcCtD
Imatinib—Immune system disorder—Etoposide—brain cancer	0.00011	0.000809	CcSEcCtD
Imatinib—Mediastinal disorder—Etoposide—brain cancer	0.00011	0.000808	CcSEcCtD
Imatinib—Thrombocytopenia—Carmustine—brain cancer	0.00011	0.000806	CcSEcCtD
Imatinib—Body temperature increased—Hydroxyurea—brain cancer	0.00011	0.000805	CcSEcCtD
Imatinib—Chills—Etoposide—brain cancer	0.00011	0.000804	CcSEcCtD
Imatinib—Tachycardia—Carmustine—brain cancer	0.000109	0.000803	CcSEcCtD
Imatinib—Confusional state—Temozolomide—brain cancer	0.000109	0.000802	CcSEcCtD
Imatinib—Anaphylactic shock—Temozolomide—brain cancer	0.000108	0.000796	CcSEcCtD
Imatinib—Oedema—Temozolomide—brain cancer	0.000108	0.000796	CcSEcCtD
Imatinib—Alopecia—Etoposide—brain cancer	0.000108	0.000792	CcSEcCtD
Imatinib—Infection—Temozolomide—brain cancer	0.000108	0.00079	CcSEcCtD
Imatinib—PTGS1—endocrine gland—brain cancer	0.000107	0.00157	CbGeAlD
Imatinib—Anorexia—Carmustine—brain cancer	0.000107	0.000785	CcSEcCtD
Imatinib—Nausea—Procarbazine—brain cancer	0.000106	0.000782	CcSEcCtD
Imatinib—Nervous system disorder—Temozolomide—brain cancer	0.000106	0.00078	CcSEcCtD
Imatinib—Thrombocytopenia—Temozolomide—brain cancer	0.000106	0.000779	CcSEcCtD
Imatinib—PTGS1—head—brain cancer	0.000106	0.00155	CbGeAlD
Imatinib—Skin disorder—Temozolomide—brain cancer	0.000105	0.000773	CcSEcCtD
Imatinib—Hypotension—Carmustine—brain cancer	0.000105	0.000769	CcSEcCtD
Imatinib—Hyperhidrosis—Temozolomide—brain cancer	0.000105	0.000769	CcSEcCtD
Imatinib—Dysgeusia—Etoposide—brain cancer	0.000104	0.000764	CcSEcCtD
Imatinib—Anorexia—Temozolomide—brain cancer	0.000103	0.000758	CcSEcCtD
Imatinib—Back pain—Etoposide—brain cancer	0.000103	0.000755	CcSEcCtD
Imatinib—Hypersensitivity—Hydroxyurea—brain cancer	0.000102	0.00075	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000102	0.00075	CcSEcCtD
Imatinib—Muscle spasms—Etoposide—brain cancer	0.000102	0.00075	CcSEcCtD
Imatinib—Insomnia—Carmustine—brain cancer	0.000101	0.000745	CcSEcCtD
Imatinib—ABCB1—telencephalon—brain cancer	0.000101	0.00148	CbGeAlD
Imatinib—Paraesthesia—Carmustine—brain cancer	0.000101	0.000739	CcSEcCtD
Imatinib—Dyspnoea—Carmustine—brain cancer	0.0001	0.000734	CcSEcCtD
Imatinib—Somnolence—Carmustine—brain cancer	9.97e-05	0.000732	CcSEcCtD
Imatinib—Asthenia—Hydroxyurea—brain cancer	9.95e-05	0.000731	CcSEcCtD
Imatinib—CA2—brain—brain cancer	9.95e-05	0.00146	CbGeAlD
Imatinib—Musculoskeletal discomfort—Temozolomide—brain cancer	9.88e-05	0.000725	CcSEcCtD
Imatinib—Ill-defined disorder—Etoposide—brain cancer	9.86e-05	0.000724	CcSEcCtD
Imatinib—Anaemia—Etoposide—brain cancer	9.82e-05	0.000721	CcSEcCtD
Imatinib—Insomnia—Temozolomide—brain cancer	9.8e-05	0.00072	CcSEcCtD
Imatinib—Decreased appetite—Carmustine—brain cancer	9.75e-05	0.000716	CcSEcCtD
Imatinib—Paraesthesia—Temozolomide—brain cancer	9.73e-05	0.000714	CcSEcCtD
Imatinib—Gastrointestinal disorder—Carmustine—brain cancer	9.68e-05	0.000711	CcSEcCtD
Imatinib—PTGS1—central nervous system—brain cancer	9.68e-05	0.00142	CbGeAlD
Imatinib—Dyspnoea—Temozolomide—brain cancer	9.66e-05	0.000709	CcSEcCtD
Imatinib—Somnolence—Temozolomide—brain cancer	9.64e-05	0.000707	CcSEcCtD
Imatinib—Constipation—Carmustine—brain cancer	9.59e-05	0.000704	CcSEcCtD
Imatinib—Pain—Carmustine—brain cancer	9.59e-05	0.000704	CcSEcCtD
Imatinib—Malaise—Etoposide—brain cancer	9.58e-05	0.000703	CcSEcCtD
Imatinib—Vertigo—Etoposide—brain cancer	9.55e-05	0.000701	CcSEcCtD
Imatinib—Dyspepsia—Temozolomide—brain cancer	9.54e-05	0.0007	CcSEcCtD
Imatinib—Leukopenia—Etoposide—brain cancer	9.51e-05	0.000698	CcSEcCtD
Imatinib—Diarrhoea—Hydroxyurea—brain cancer	9.49e-05	0.000697	CcSEcCtD
Imatinib—Decreased appetite—Temozolomide—brain cancer	9.42e-05	0.000692	CcSEcCtD
Imatinib—Gastrointestinal disorder—Temozolomide—brain cancer	9.36e-05	0.000687	CcSEcCtD
Imatinib—Fatigue—Temozolomide—brain cancer	9.35e-05	0.000686	CcSEcCtD
Imatinib—Loss of consciousness—Etoposide—brain cancer	9.34e-05	0.000686	CcSEcCtD
Imatinib—Cough—Etoposide—brain cancer	9.27e-05	0.000681	CcSEcCtD
Imatinib—Pain—Temozolomide—brain cancer	9.27e-05	0.00068	CcSEcCtD
Imatinib—Constipation—Temozolomide—brain cancer	9.27e-05	0.00068	CcSEcCtD
Imatinib—Feeling abnormal—Carmustine—brain cancer	9.24e-05	0.000678	CcSEcCtD
Imatinib—ABCG2—brain—brain cancer	9.22e-05	0.00135	CbGeAlD
Imatinib—Convulsion—Etoposide—brain cancer	9.21e-05	0.000676	CcSEcCtD
Imatinib—Hypertension—Etoposide—brain cancer	9.18e-05	0.000673	CcSEcCtD
Imatinib—Dizziness—Hydroxyurea—brain cancer	9.18e-05	0.000673	CcSEcCtD
Imatinib—Gastrointestinal pain—Carmustine—brain cancer	9.17e-05	0.000673	CcSEcCtD
Imatinib—Chest pain—Etoposide—brain cancer	9.05e-05	0.000664	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	8.99e-05	0.00066	CcSEcCtD
Imatinib—CYP3A4—endocrine gland—brain cancer	8.97e-05	0.00131	CbGeAlD
Imatinib—Discomfort—Etoposide—brain cancer	8.94e-05	0.000656	CcSEcCtD
Imatinib—Feeling abnormal—Temozolomide—brain cancer	8.93e-05	0.000656	CcSEcCtD
Imatinib—Abdominal pain—Carmustine—brain cancer	8.87e-05	0.000651	CcSEcCtD
Imatinib—Body temperature increased—Carmustine—brain cancer	8.87e-05	0.000651	CcSEcCtD
Imatinib—Gastrointestinal pain—Temozolomide—brain cancer	8.86e-05	0.000651	CcSEcCtD
Imatinib—CYP2D6—endocrine gland—brain cancer	8.83e-05	0.00129	CbGeAlD
Imatinib—Vomiting—Hydroxyurea—brain cancer	8.82e-05	0.000647	CcSEcCtD
Imatinib—Rash—Hydroxyurea—brain cancer	8.75e-05	0.000642	CcSEcCtD
Imatinib—Confusional state—Etoposide—brain cancer	8.75e-05	0.000642	CcSEcCtD
Imatinib—Dermatitis—Hydroxyurea—brain cancer	8.74e-05	0.000642	CcSEcCtD
Imatinib—CYP2D6—head—brain cancer	8.72e-05	0.00128	CbGeAlD
Imatinib—Headache—Hydroxyurea—brain cancer	8.69e-05	0.000638	CcSEcCtD
Imatinib—Anaphylactic shock—Etoposide—brain cancer	8.67e-05	0.000637	CcSEcCtD
Imatinib—Infection—Etoposide—brain cancer	8.62e-05	0.000632	CcSEcCtD
Imatinib—Urticaria—Temozolomide—brain cancer	8.61e-05	0.000632	CcSEcCtD
Imatinib—Abdominal pain—Temozolomide—brain cancer	8.57e-05	0.000629	CcSEcCtD
Imatinib—Body temperature increased—Temozolomide—brain cancer	8.57e-05	0.000629	CcSEcCtD
Imatinib—Thrombocytopenia—Etoposide—brain cancer	8.49e-05	0.000623	CcSEcCtD
Imatinib—Tachycardia—Etoposide—brain cancer	8.47e-05	0.000621	CcSEcCtD
Imatinib—Skin disorder—Etoposide—brain cancer	8.42e-05	0.000618	CcSEcCtD
Imatinib—ABCB1—gonad—brain cancer	8.41e-05	0.00123	CbGeAlD
Imatinib—Hyperhidrosis—Etoposide—brain cancer	8.39e-05	0.000615	CcSEcCtD
Imatinib—Anorexia—Etoposide—brain cancer	8.27e-05	0.000607	CcSEcCtD
Imatinib—Hypersensitivity—Carmustine—brain cancer	8.26e-05	0.000607	CcSEcCtD
Imatinib—Nausea—Hydroxyurea—brain cancer	8.24e-05	0.000605	CcSEcCtD
Imatinib—ABCB1—pituitary gland—brain cancer	8.2e-05	0.0012	CbGeAlD
Imatinib—Hypotension—Etoposide—brain cancer	8.1e-05	0.000595	CcSEcCtD
Imatinib—CYP3A4—central nervous system—brain cancer	8.09e-05	0.00118	CbGeAlD
Imatinib—Asthenia—Carmustine—brain cancer	8.05e-05	0.000591	CcSEcCtD
Imatinib—Hypersensitivity—Temozolomide—brain cancer	7.99e-05	0.000586	CcSEcCtD
Imatinib—CYP2D6—central nervous system—brain cancer	7.96e-05	0.00117	CbGeAlD
Imatinib—ABCB1—medulla oblongata—brain cancer	7.91e-05	0.00116	CbGeAlD
Imatinib—Paraesthesia—Etoposide—brain cancer	7.79e-05	0.000572	CcSEcCtD
Imatinib—CYP2D6—cerebellum—brain cancer	7.78e-05	0.00114	CbGeAlD
Imatinib—Asthenia—Temozolomide—brain cancer	7.78e-05	0.000571	CcSEcCtD
Imatinib—Dyspnoea—Etoposide—brain cancer	7.73e-05	0.000568	CcSEcCtD
Imatinib—Somnolence—Etoposide—brain cancer	7.71e-05	0.000566	CcSEcCtD
Imatinib—PTGS1—brain—brain cancer	7.69e-05	0.00113	CbGeAlD
Imatinib—Diarrhoea—Carmustine—brain cancer	7.67e-05	0.000563	CcSEcCtD
Imatinib—Pruritus—Temozolomide—brain cancer	7.67e-05	0.000563	CcSEcCtD
Imatinib—Decreased appetite—Etoposide—brain cancer	7.54e-05	0.000553	CcSEcCtD
Imatinib—Gastrointestinal disorder—Etoposide—brain cancer	7.49e-05	0.00055	CcSEcCtD
Imatinib—Fatigue—Etoposide—brain cancer	7.48e-05	0.000549	CcSEcCtD
Imatinib—Dizziness—Carmustine—brain cancer	7.42e-05	0.000544	CcSEcCtD
Imatinib—Constipation—Etoposide—brain cancer	7.42e-05	0.000544	CcSEcCtD
Imatinib—Pain—Etoposide—brain cancer	7.42e-05	0.000544	CcSEcCtD
Imatinib—Diarrhoea—Temozolomide—brain cancer	7.42e-05	0.000544	CcSEcCtD
Imatinib—ABCB1—midbrain—brain cancer	7.23e-05	0.00106	CbGeAlD
Imatinib—Dizziness—Temozolomide—brain cancer	7.17e-05	0.000526	CcSEcCtD
Imatinib—Feeling abnormal—Etoposide—brain cancer	7.15e-05	0.000525	CcSEcCtD
Imatinib—Vomiting—Carmustine—brain cancer	7.13e-05	0.000523	CcSEcCtD
Imatinib—Gastrointestinal pain—Etoposide—brain cancer	7.09e-05	0.000521	CcSEcCtD
Imatinib—Rash—Carmustine—brain cancer	7.07e-05	0.000519	CcSEcCtD
Imatinib—Dermatitis—Carmustine—brain cancer	7.07e-05	0.000519	CcSEcCtD
Imatinib—ABCB1—spinal cord—brain cancer	7.06e-05	0.00103	CbGeAlD
Imatinib—Headache—Carmustine—brain cancer	7.03e-05	0.000516	CcSEcCtD
Imatinib—Vomiting—Temozolomide—brain cancer	6.89e-05	0.000506	CcSEcCtD
Imatinib—Urticaria—Etoposide—brain cancer	6.89e-05	0.000506	CcSEcCtD
Imatinib—Body temperature increased—Etoposide—brain cancer	6.86e-05	0.000503	CcSEcCtD
Imatinib—Abdominal pain—Etoposide—brain cancer	6.86e-05	0.000503	CcSEcCtD
Imatinib—Rash—Temozolomide—brain cancer	6.83e-05	0.000502	CcSEcCtD
Imatinib—Dermatitis—Temozolomide—brain cancer	6.83e-05	0.000501	CcSEcCtD
Imatinib—Headache—Temozolomide—brain cancer	6.79e-05	0.000498	CcSEcCtD
Imatinib—Nausea—Carmustine—brain cancer	6.66e-05	0.000489	CcSEcCtD
Imatinib—Nausea—Temozolomide—brain cancer	6.44e-05	0.000473	CcSEcCtD
Imatinib—Hypersensitivity—Etoposide—brain cancer	6.39e-05	0.000469	CcSEcCtD
Imatinib—ABCB1—endocrine gland—brain cancer	6.35e-05	0.000931	CbGeAlD
Imatinib—CYP2D6—brain—brain cancer	6.32e-05	0.000925	CbGeAlD
Imatinib—ABCB1—head—brain cancer	6.27e-05	0.000919	CbGeAlD
Imatinib—Asthenia—Etoposide—brain cancer	6.22e-05	0.000457	CcSEcCtD
Imatinib—Pruritus—Etoposide—brain cancer	6.14e-05	0.00045	CcSEcCtD
Imatinib—Diarrhoea—Etoposide—brain cancer	5.93e-05	0.000436	CcSEcCtD
Imatinib—Dizziness—Etoposide—brain cancer	5.74e-05	0.000421	CcSEcCtD
Imatinib—ABCB1—central nervous system—brain cancer	5.72e-05	0.000839	CbGeAlD
Imatinib—ABCB1—cerebellum—brain cancer	5.6e-05	0.00082	CbGeAlD
Imatinib—Vomiting—Etoposide—brain cancer	5.51e-05	0.000405	CcSEcCtD
Imatinib—Rash—Etoposide—brain cancer	5.47e-05	0.000401	CcSEcCtD
Imatinib—Dermatitis—Etoposide—brain cancer	5.46e-05	0.000401	CcSEcCtD
Imatinib—Headache—Etoposide—brain cancer	5.43e-05	0.000399	CcSEcCtD
Imatinib—Nausea—Etoposide—brain cancer	5.15e-05	0.000378	CcSEcCtD
Imatinib—ABCB1—brain—brain cancer	4.54e-05	0.000666	CbGeAlD
Imatinib—SLC22A2—Metabolism—ENO2—brain cancer	9.83e-06	0.00011	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	9.83e-06	0.00011	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—SPP1—brain cancer	9.82e-06	0.00011	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—CTNNB1—brain cancer	9.81e-06	0.00011	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—PDGFRA—brain cancer	9.77e-06	0.00011	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—RELA—brain cancer	9.76e-06	0.00011	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—CTNNB1—brain cancer	9.75e-06	0.000109	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—ERBB2—brain cancer	9.7e-06	0.000109	CbGpPWpGaD
Imatinib—LCK—Immune System—VAV1—brain cancer	9.58e-06	0.000107	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ENO2—brain cancer	9.54e-06	0.000107	CbGpPWpGaD
Imatinib—ABL1—Immune System—PDGFRA—brain cancer	9.52e-06	0.000107	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IRS2—brain cancer	9.52e-06	0.000107	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP2C9—brain cancer	9.52e-06	0.000107	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NOTCH2—brain cancer	9.49e-06	0.000106	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HES1—brain cancer	9.48e-06	0.000106	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—IL2—brain cancer	9.47e-06	0.000106	CbGpPWpGaD
Imatinib—KIT—Disease—IRS2—brain cancer	9.29e-06	0.000104	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP2C9—brain cancer	9.29e-06	0.000104	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ENO2—brain cancer	9.16e-06	0.000103	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	9.09e-06	0.000102	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VAV1—brain cancer	9.05e-06	0.000102	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PDGFRA—brain cancer	9.02e-06	0.000101	CbGpPWpGaD
Imatinib—ALB—Metabolism—BSG—brain cancer	9.01e-06	0.000101	CbGpPWpGaD
Imatinib—CA9—Metabolism—PIK3CG—brain cancer	9.01e-06	0.000101	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—IDH1—brain cancer	9e-06	0.000101	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	9e-06	0.000101	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NOTCH2—brain cancer	8.98e-06	0.000101	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IRS2—brain cancer	8.88e-06	9.96e-05	CbGpPWpGaD
Imatinib—LCK—Disease—VAV1—brain cancer	8.84e-06	9.92e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—CTNNB1—brain cancer	8.84e-06	9.92e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IRS2—brain cancer	8.79e-06	9.86e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP2C9—brain cancer	8.75e-06	9.82e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—CTNNB1—brain cancer	8.61e-06	9.66e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—VEGFA—brain cancer	8.59e-06	9.63e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IRS2—brain cancer	8.58e-06	9.63e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SHH—brain cancer	8.57e-06	9.62e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VAV1—brain cancer	8.57e-06	9.61e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—STAT3—brain cancer	8.5e-06	9.54e-05	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—VEGFA—brain cancer	8.42e-06	9.45e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IRS2—brain cancer	8.36e-06	9.38e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TRPC6—brain cancer	8.27e-06	9.27e-05	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—EGFR—brain cancer	8.21e-06	9.21e-05	CbGpPWpGaD
Imatinib—KIT—Disease—APC—brain cancer	8.2e-06	9.2e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—IL2—brain cancer	8.16e-06	9.16e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—RELA—brain cancer	8.16e-06	9.15e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTCH1—brain cancer	8.13e-06	9.12e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SMO—brain cancer	8.13e-06	9.12e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—ERBB2—brain cancer	8.11e-06	9.09e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NOTCH2—brain cancer	8.09e-06	9.08e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—BSG—brain cancer	8.09e-06	9.08e-05	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—VEGFA—brain cancer	8.04e-06	9.02e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IRS2—brain cancer	7.92e-06	8.89e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	7.92e-06	8.89e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—BSG—brain cancer	7.9e-06	8.86e-05	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—EGFR—brain cancer	7.89e-06	8.85e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PDGFRA—brain cancer	7.84e-06	8.8e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PIK3CG—brain cancer	7.84e-06	8.8e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—APC—brain cancer	7.84e-06	8.8e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—RELA—brain cancer	7.83e-06	8.79e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—ERBB2—brain cancer	7.79e-06	8.73e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HES1—brain cancer	7.78e-06	8.73e-05	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—EGFR—brain cancer	7.77e-06	8.72e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—APC—brain cancer	7.77e-06	8.71e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—IDH1—brain cancer	7.75e-06	8.7e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—EGFR—brain cancer	7.73e-06	8.67e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VAV1—brain cancer	7.72e-06	8.66e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HES1—brain cancer	7.61e-06	8.53e-05	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—EGFR—brain cancer	7.46e-06	8.37e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—BSG—brain cancer	7.44e-06	8.35e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP2C9—brain cancer	7.42e-06	8.32e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PDGFRA—brain cancer	7.41e-06	8.31e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—BSG—brain cancer	7.38e-06	8.28e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HES1—brain cancer	7.37e-06	8.26e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	7.29e-06	8.17e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PDGFRA—brain cancer	7.24e-06	8.12e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SPP1—brain cancer	7.19e-06	8.07e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	7.13e-06	8e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ENO2—brain cancer	7.12e-06	7.98e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CTNNB1—brain cancer	7.09e-06	7.96e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—EGFR—brain cancer	7e-06	7.86e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—APC—brain cancer	7e-06	7.85e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—IDH1—brain cancer	6.96e-06	7.81e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—RELA—brain cancer	6.94e-06	7.79e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—VEGFA—brain cancer	6.94e-06	7.78e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PIK3CG—brain cancer	6.93e-06	7.78e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—ERBB2—brain cancer	6.9e-06	7.74e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IRS2—brain cancer	6.89e-06	7.72e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—EGFR—brain cancer	6.82e-06	7.66e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SPP1—brain cancer	6.81e-06	7.64e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—IDH1—brain cancer	6.79e-06	7.62e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—EGFR—brain cancer	6.72e-06	7.54e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HES1—brain cancer	6.64e-06	7.44e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—RELA—brain cancer	6.57e-06	7.37e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—ERBB2—brain cancer	6.53e-06	7.33e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IRS2—brain cancer	6.51e-06	7.3e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NOTCH2—brain cancer	6.5e-06	7.29e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—IDH1—brain cancer	6.4e-06	7.18e-05	CbGpPWpGaD
Imatinib—KIT—Disease—ERBB2—brain cancer	6.37e-06	7.15e-05	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—brain cancer	6.36e-06	7.14e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IRS2—brain cancer	6.36e-06	7.13e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—IDH1—brain cancer	6.35e-06	7.12e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PDGFRA—brain cancer	6.32e-06	7.09e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	6.31e-06	7.08e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—BSG—brain cancer	6.31e-06	7.07e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL2—brain cancer	6.25e-06	7.02e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VAV1—brain cancer	6.19e-06	6.95e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IRS2—brain cancer	6.16e-06	6.91e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SPP1—brain cancer	6.13e-06	6.88e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—ENO2—brain cancer	6.13e-06	6.87e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—RELA—brain cancer	6.13e-06	6.87e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—ERBB2—brain cancer	6.09e-06	6.83e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—CTNNB1—brain cancer	6.04e-06	6.77e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—ERBB2—brain cancer	6.03e-06	6.76e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	5.98e-06	6.71e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—RELA—brain cancer	5.92e-06	6.64e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL2—brain cancer	5.92e-06	6.64e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—ERBB2—brain cancer	5.88e-06	6.6e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—RELA—brain cancer	5.77e-06	6.47e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CG—brain cancer	5.75e-06	6.45e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—APC—brain cancer	5.75e-06	6.45e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—ERBB2—brain cancer	5.73e-06	6.43e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP2C9—brain cancer	5.72e-06	6.42e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CTNNB1—brain cancer	5.71e-06	6.41e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.67e-06	6.36e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—EGFR—brain cancer	5.62e-06	6.3e-05	CbGpPWpGaD
Imatinib—LCK—Disease—APC—brain cancer	5.62e-06	6.3e-05	CbGpPWpGaD
Imatinib—KIT—Disease—CTNNB1—brain cancer	5.57e-06	6.25e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IRS2—brain cancer	5.55e-06	6.22e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL2—brain cancer	5.52e-06	6.19e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ENO2—brain cancer	5.5e-06	6.17e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CG—brain cancer	5.44e-06	6.1e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—APC—brain cancer	5.44e-06	6.1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—ERBB2—brain cancer	5.43e-06	6.09e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—IDH1—brain cancer	5.42e-06	6.08e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—EGFR—brain cancer	5.4e-06	6.05e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CCND1—brain cancer	5.38e-06	6.03e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ENO2—brain cancer	5.37e-06	6.02e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL2—brain cancer	5.33e-06	5.98e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CTNNB1—brain cancer	5.33e-06	5.98e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HES1—brain cancer	5.33e-06	5.97e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CTNNB1—brain cancer	5.28e-06	5.92e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—STAT3—brain cancer	5.26e-06	5.9e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—brain cancer	5.24e-06	5.88e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL2—brain cancer	5.2e-06	5.83e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.17e-06	5.8e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CTNNB1—brain cancer	5.15e-06	5.78e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PDGFRA—brain cancer	5.07e-06	5.69e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ENO2—brain cancer	5.06e-06	5.68e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—CTNNB1—brain cancer	5.02e-06	5.63e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ENO2—brain cancer	5.02e-06	5.63e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—STAT3—brain cancer	4.98e-06	5.59e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SPP1—brain cancer	4.92e-06	5.52e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CG—brain cancer	4.9e-06	5.5e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—APC—brain cancer	4.9e-06	5.5e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IL2—brain cancer	4.88e-06	5.47e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—BSG—brain cancer	4.87e-06	5.46e-05	CbGpPWpGaD
Imatinib—KIT—Disease—STAT3—brain cancer	4.86e-06	5.45e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—EGFR—brain cancer	4.78e-06	5.37e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CTNNB1—brain cancer	4.75e-06	5.33e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—RELA—brain cancer	4.75e-06	5.33e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—ERBB2—brain cancer	4.72e-06	5.3e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—VEGFA—brain cancer	4.69e-06	5.26e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—STAT3—brain cancer	4.64e-06	5.21e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—STAT3—brain cancer	4.6e-06	5.16e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CG—brain cancer	4.56e-06	5.11e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—EGFR—brain cancer	4.53e-06	5.08e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CG—brain cancer	4.52e-06	5.07e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MYC—brain cancer	4.51e-06	5.06e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CG—brain cancer	4.51e-06	5.06e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—RELA—brain cancer	4.49e-06	5.04e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—STAT3—brain cancer	4.49e-06	5.03e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—ERBB2—brain cancer	4.46e-06	5e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IRS2—brain cancer	4.45e-06	4.99e-05	CbGpPWpGaD
Imatinib—KIT—Disease—EGFR—brain cancer	4.42e-06	4.95e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	4.41e-06	4.95e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CG—brain cancer	4.38e-06	4.91e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—STAT3—brain cancer	4.37e-06	4.91e-05	CbGpPWpGaD
Imatinib—LCK—Disease—ERBB2—brain cancer	4.36e-06	4.89e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MYC—brain cancer	4.31e-06	4.84e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ENO2—brain cancer	4.29e-06	4.81e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL2—brain cancer	4.28e-06	4.8e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MYC—brain cancer	4.27e-06	4.79e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—RELA—brain cancer	4.25e-06	4.77e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ERBB2—brain cancer	4.22e-06	4.74e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EGFR—brain cancer	4.22e-06	4.73e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CG—brain cancer	4.2e-06	4.71e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—IDH1—brain cancer	4.18e-06	4.69e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EGFR—brain cancer	4.18e-06	4.69e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—VEGFA—brain cancer	4.15e-06	4.65e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—STAT3—brain cancer	4.14e-06	4.65e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CTNNB1—brain cancer	4.13e-06	4.63e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EGFR—brain cancer	4.08e-06	4.58e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL2—brain cancer	4.04e-06	4.54e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EGFR—brain cancer	3.97e-06	4.46e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCND1—brain cancer	3.94e-06	4.42e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CG—brain cancer	3.93e-06	4.41e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—APC—brain cancer	3.93e-06	4.41e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CTNNB1—brain cancer	3.9e-06	4.38e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MYC—brain cancer	3.85e-06	4.32e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RELA—brain cancer	3.83e-06	4.29e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2—brain cancer	3.83e-06	4.29e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CTNNB1—brain cancer	3.81e-06	4.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ERBB2—brain cancer	3.8e-06	4.27e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—brain cancer	3.77e-06	4.22e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCND1—brain cancer	3.73e-06	4.19e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CTNNB1—brain cancer	3.69e-06	4.14e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—brain cancer	3.6e-06	4.04e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—brain cancer	3.54e-06	3.97e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2—brain cancer	3.45e-06	3.87e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—brain cancer	3.44e-06	3.85e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—brain cancer	3.4e-06	3.82e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—brain cancer	3.36e-06	3.77e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CTNNB1—brain cancer	3.33e-06	3.73e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—brain cancer	3.33e-06	3.73e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ENO2—brain cancer	3.31e-06	3.71e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—brain cancer	3.27e-06	3.67e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CG—brain cancer	3.26e-06	3.66e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—brain cancer	3.25e-06	3.65e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—brain cancer	3.22e-06	3.61e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—brain cancer	3.16e-06	3.55e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—brain cancer	3.13e-06	3.51e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—brain cancer	3.09e-06	3.47e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—brain cancer	3.09e-06	3.47e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RELA—brain cancer	3.07e-06	3.45e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—brain cancer	3.05e-06	3.42e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—brain cancer	3.02e-06	3.39e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—brain cancer	2.99e-06	3.36e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—brain cancer	2.93e-06	3.29e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—brain cancer	2.93e-06	3.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—brain cancer	2.9e-06	3.25e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CG—brain cancer	2.81e-06	3.15e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—brain cancer	2.77e-06	3.1e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—brain cancer	2.7e-06	3.03e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—brain cancer	2.7e-06	3.02e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CTNNB1—brain cancer	2.67e-06	3e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—brain cancer	2.64e-06	2.96e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—brain cancer	2.6e-06	2.91e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CG—brain cancer	2.52e-06	2.83e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CG—brain cancer	2.46e-06	2.76e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—brain cancer	2.46e-06	2.76e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—brain cancer	2.35e-06	2.64e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—brain cancer	2.33e-06	2.61e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CG—brain cancer	2.32e-06	2.6e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CG—brain cancer	2.3e-06	2.58e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—brain cancer	2.21e-06	2.48e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—brain cancer	2.16e-06	2.43e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—brain cancer	2.12e-06	2.37e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CG—brain cancer	1.97e-06	2.21e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—brain cancer	1.78e-06	1.99e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CG—brain cancer	1.52e-06	1.7e-05	CbGpPWpGaD
